Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Open-Label Study to Evaluate Safety, Pharmacokinetics, and Preliminary Anti-Tumor Activity of STRO-004 in Adults With Refractory/Recurrent Metastatic Solid Tumors

NCT07227168 is registered in ClinicalTrials.gov with Sutro Biopharma, Inc. as lead sponsor.

NCT NCT07227168
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07227168 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Open-Label Study to Evaluate Safety, Pharmacokinetics, and Preliminary Anti-Tumor Activity of STRO-004 in Adults With Refractory/Recurrent Metastatic Solid Tumors
Lead sponsor
Sutro Biopharma, Inc.
Phase
Phase 1
Overall status
Recruiting
Start date
November 7, 2025
Completion date
April 30, 2028
Enrollment
200 (estimated)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

cervical cancer, colorectal cancer, endometrial cancer, esophageal cancer, gastric cancer, head and neck squamous cell carcinoma hnscc, non-small cell lung cancer nsclc, pancreatic ductal adenocarcinoma (pdac), urothelial cancer